Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Schedule of net revenue from collaboration arrangement

Net revenue recognized under our GSK Agreements was as follows:

	Three Months Ended March 31,
(In thousands)	2024			2023
Royalties    - RELVAR/BREO	$	52,138		$	50,883
Royalties    - ANORO		9,733			9,431
Total royalties		61,871			60,314
Less: amortization of capitalized fees paid		(3,456	)		(3,456	)
Total net royalty revenue	$	58,415		$	56,858